Navigation Links
New Report Just Published: World Multiple Myeloma Therapeutics Market Report
Date:7/7/2009

NEW YORK, July 7 /PRNewswire/ -- Reportlinker.com just added a new market research report to its catalogue.

World Multiple Myeloma Therapeutics Market

http://www.reportlinker.com/p0119496/World-Multiple-Myeloma-Therapeutics-Market.html?utm_source=PRNWire&utm_medium=PR&utm_campaign=PRNWire

This report analyzes the US market for Multiple Myeloma Therapeutics in Millions of US$. The market for multiple myeloma therapeutics is analyzed by the following Drugs: Thalomid, Revlimid, Velcade, and Others. The market for multiple myeloma therapeutics is also analyzed by the Lines of Treatment -- Induction Therapy for SCT Candidates, Induction Therapy for Non-SCT Candidates, and Therapy for Relapsed or Refractory Myeloma. Annual forecasts are provided for the period of 2006 through 2015. The report profiles 98 companies including many key and niche players such as Amgen Inc., Avalon Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Kosan Biosciences, Inc., Celgene Corporation, F. Hoffmann-La Roche Ltd, Genentech, Inc., Genta Incorporated, Millennium Pharmaceuticals, Ortho Biotech Products, LP, Seattle Genetics, and Ziopharm Oncology, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

    MULTIPLE MYELOMA THERAPEUTICS
    A US MARKET REPORT MCP-1857


    CONTENTS


    I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

    Study Reliability and Reporting Limitations I-1
    Disclaimers I-2
    Data Interpretation & Reporting Level I-2
    Quantitative Techniques & Analytics I-3
    Product Definitions and Scope of Study I-3


    II. A US MARKET REPORT

    1. Industry Overview II-1
    Hematological Cancer Therapies: A Prelude II-1
    Treatment Regimes: The Golden Rule II-1
    Multiple Myeloma: A Second Most Common Hematological Cancer II-2

    Table 1: Hematological Malignancies in the US (2007): Number
    of Incidences and Deaths by Type of Cancer - Lymphoma
    (Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma), Multiple Myeloma,
    Leukemia (Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia,
    Acute Myeloid Leukemia, Chronic Myeloid Leukemia, and Other Leukemia),
    and Myelodysplastic Syndromes (MDS) (includes corresponding Graph/Chart)
    II-3

    Table 2: Blood Cancer Statistics in the US (2008E):
    Percentage Breakdown of Hematological Cancer Cases by Type:
    Lymphoma, Myeloma, and Leukemia (includes corresponding
    Graph/Chart) II-3

    Table 3: Multiple Myeloma Statistics in the US (2008E):
    Number of Persons Undergoing Initial Diagnosis and Monitoring
    (includes corresponding Graph/Chart) II-4
    Treatment Therapies: Move Up the Learning Curve II-4
    Risk-Adapted Therapy: The New Norm of Future Treatment II-5
    New Generation Drugs in the Arsenal Against Multiple Myeloma II-5
    Velcade(R) (Bortezomib) II-5
    Thalomid(R) (Thalidomide) II-5
    Revlimid(R) (Lenalidomide) II-6
    Alkeran (Melphalan) II-6
    Doxil (Liposomal Doxorubicin) II-6
    Trisenox(R) (Arsenic trioxide) II-6
    Noteworthy Issues Related to Major Drugs: An Evaluation of
    Pros and Cons II-7
    Revlimid Overtakes Thalomid: Why? II-7
    How Effective Will Thalomid Be in the 3rd Line Setting?
    Skepticism Overflows II-7
    Revlimid Impedes Stem Cell Harvesting!!: What's the Truth? II-7
    1st & 2nd Generation Geldanamycin Analog to Do Wonders for
    Myeloma Treatment II-8
    Other Trends & Issues II-8
    Approval of New Generation Drugs Push the Market Into the
    Bulge Bracket II-8
    Growth Fundamentals Get Stronger II-8

    Table 4: Key Drug Regimens in the US Multiple Myeloma Market (2006):
    Breakdown of Typical Length of Treatment
    Cycle and Cost per Cycle (In US$) (includes corresponding
    Graph/Chart) II-9
    Multidrug Resistance: A Challenge to Reckon With II-9
    Gene Therapy Exudes Hope II-9
    Challenges Encountered in Clinical Trials II-10
    FDA's Antidotes II-10
    Europe Lagging Behind in Drug Approvals II-11

    Table 5: Multiple Myeloma Market in Europe (2006):
    Percentage Breakdown of Drugs Used in First Line Treatment -
    Melphalan, Thalidomide, Velcade, Doxorubicin, and Others
    (includes corresponding Graph/Chart) II-11

    Table 6: Multiple Myeloma Market in Europe (2006):
    Percentage Breakdown of Drugs Used in Second Line Treatment -
    Melphalan, Thalidomide, Velcade, and Doxorubicin
    (includes corresponding Graph/Chart) II-11

    Table 7: Multiple Myeloma Market in Europe (2006):
    Percentage Breakdown of Drugs Used in Third Line Treatment -
    Melphalan, Thalidomide, Velcade, Doxorubicin, and Others
    (includes corresponding Graph/Chart) II-12
    Market Share Statistics II-12
    Present Batting Order II-12

    Table 8: US Market for Multiple Myeloma Therapeutics
    (2006): Percentage Breakdown of Revenues by Company -
    Celgene Corporation, Millennium Pharmaceuticals,
    Ortho-Biotech, and Others (includes corresponding
    Graph/Chart) II-12
    Looking Through the Crystal Ball: Year 2013 II-12

    Table 9: US Market for Multiple Myeloma Therapeutics
    (2013P): Percentage Breakdown of Revenues by Company -
    Celgene Corporation, Millennium Pharmaceuticals Inc, Kosan
    Biosciences, Ortho Biotech, Ziopharm Oncology Inc and
    Others (includes corresponding Graph/Chart) II-12
    Oncology and Hematology Market II-13

    Table 10: Leading Players in the Oncology and Hematology Market in
    the US (2008E): Percentage Breakdown of Value
    Sales by Company - Amgen, Roche, Novartis, DNA,
    AstraZeneca, and Others (includes corresponding
    Graph/Chart) II-13
    Drugs Approved & In Pipeline: A Review II-13
    Multiple Myeloma Drugs Approved by the FDA As of the Year 2008 II-13
    Multiple Myeloma Drugs in Pipeline in the US As of the Year
    2008 II-14
    Phase III Drugs in Pipeline II-14
    Phase II Drugs in Pipeline II-15
    Phase I Drugs in Pipeline II-21
    Key Non-Profit Organizations in the US II-25
    Multiple Myeloma Research Foundation (MMRF) II-25
    National Coalition for Cancer Survivorship (NCCS) II-25
    National Marrow Donor Program (NMDP) II-25
    Oregon Health and Science University Cancer Institute II-25

    2. Disease & Treatment Overview II-26
    Cancer: A Definition II-26
    Hematological Cancers II-26
    Types of Hematological Cancer II-26
    Multiple Myeloma II-26
    Multiple Myeloma Stages II-27
    Stage I II-27
    Stage II/III II-27
    Treatment Procedures II-27
    Diagnosis II-27
    Treatment II-28
    Initial Treatment Regimen II-28
    Induction Therapy for SCT Candidates II-28
    Induction Therapy for Non-SCT Candidates II-29
    Therapy for Relapsed or Refractory Myeloma II-29
    Maintenance Therapy for Relapsed or Refractory Myeloma II-29
    Treatment Pros & Cons II-29
    Others Types of Hematological Cancers II-30
    Leukemia II-30
    Acute Lymphocytic Leukemia II-30
    Chronic Lymphocytic Leukemia II-31
    Acute Myeloid Leukemia II-31
    Chronic Myeloid Leukemia II-31
    Lymphoma II-31
    Non-Hodgkin's Lymphoma II-32
    Hodgkin's Lymphoma II-32
    Myelodysplastic Syndromes II-32
    Hematological Cancer Therapies II-33
    Chemotherapy II-33
    Radiation Therapy II-33
    Stem Cell Transplants II-33
    Biological Therapy II-34
    Targeted Therapy II-34
    Gene Therapy II-34
    Immunotherapy II-34
    Monoclonal Antibody Treatment II-35
    Vaccines II-35
    Donor Lymphocyte Infusion II-35
    Hematological Cancer Drug Classes II-35
    Hypomethylating Agents & Antimetabolites II-35
    Bisphosphonates II-36
    Alkylating Agents and DNA-Damaging Agents II-36
    DNA-Repair Enzyme Inhibitors II-36
    Histone Deacetylase Inhibitor II-36
    Immunomodulators II-36
    Proteasome Inhibitor II-36
    Tyrosine Kinase Inhibitors II-36

    3. Clinical Trials and Drug Approvals II-37
    NICE Grants Approval for Use of Revlimid(R) II-37
    SWOG Announces Closure of Phase III Trial (S0232) for Patients
    with Multiple Myeloma II-37
    Fujimoto Pharmaceutical Receives Approval to Market Thalidomide II-37
    Celgene Obtains Health Canada Approval for Revlimid Oral
    Cancer Drug II-37
    FDA Grants Orphan-Drug Designation to Melphalan II-38
    Merck Commences Phase II-b and Phase III Clinical Trial of
    Zolinza II-38
    Clavis Initiates Phase II Trial of Elacytarabine II-38
    Gilead Sciences Commences GS 9219 Phase I Clinical Trial II-38
    AstraZeneca Carries Out AZD 0530 Phase II trial II-39
    European Commission Grants Approval of Thalidomide for
    Multiple Myeloma II-39
    EMEA Issues Positive Opinion for Thalidomide Use in Multiple
    Myeloma II-39
    Global Regulatory Developments for the Use of Revlimid(R) in
    Multiple Myeloma II-39
    Takeda Gains FDA Approval to Promote Velcade II-40
    Health Canada Approves VELCADE II-40
    Genzyme Receives FDA Certification for Mozobil II-40
    Celgene's Thalidomide Pharmion Receives Marketing Authorization II-41
    Ziopharm Commences Phase II Clinical Trial of ZIO-101 II-41
    FDA Approves Pluristem's Pre-IND Application of PLX-I II-41
    Merck Pharmaceuticals Commences Phase I Study for R763 Kinase
    Inhibitor II-41
    Swissmedic Approves Celgene's REVLIMID Oral Cancer Drug II-42
    Celgene's REVLIMID Receives EU's Marketing Authorization II-42
    FDA Approves Application of Piramal's IND-P276 Multiple
    Myeloma Drug II-42
    Millennium Pharmaceuticals and Johnson & Johnson Initiate
    Velcade(R) Phase II Trial II-42
    FDA to Consider the New Drug Application Filed for Use of
    Doxil(R) Combined with Velcade(R) in Patients with Multiple
    Myeloma II-42
    Ortho Biotech Files Application with FDA for Approval of
    Combination Drug DOXIL(R) and VELCADE(R) II-43
    Caraco's Allopurinol Receives FDA Approval II-43
    FDA Approves Thalomid(R) as Combination Therapy for Multiple
    Myeloma II-43
    Revlimid(R) Obtains Regulatory Approval for the Treatment of
    Multiple Myeloma II-43
    LymphoSign Inc. Announces Successful Completion of LS104
    Drug's Pre-Clinical Testing II-43
    Seattle Genetics Commences SGN-40 Phase I Clinical Trial II-44
    FDA Approves Use of Revlimid(R) for Multiple Myeloma II-44
    US FDA Approves Use of Thalidomide for Multiple Myeloma II-44
    Ziopharm Oncology Receives Approval to Commence ZIO-101 and
    ZIO-201 Trial II-44
    FDA Grants Approval for Use of VELCADE(R) for Patients with
    Mantle Cell Lymphoma II-44

    4. Recent Industry Activity II-45
    CytRx to Acquire Innovive II-45
    Launch of Epoetin alfa Hexal II-45
    PDL and Bristol-Myers Signs Agreement II-45
    MNKD and LLS Conclude Joint Research Agreement II-45
    MorphoSys and DSM Enter into Agreement II-46
    StemCyte Enters into Joint Venture with Cadila and Apollo Hospitals
    in India II-46
    ImmunoCellular Acquires Molecular Antibody Technology II-46
    US House of Representatives Sanction the Hematological Cancer
    Research Investment and Education Act II-46
    Bayer and Cell Therapeutics Enter into Mutual Agreement II-47
    Bristol-Myers to Take Over Kosan Biosciences II-47
    Bristol and PDL BioPharma Enter into Agreement II-47
    Gamida Cell Enters Into a Agreement with Amgen II-47
    Circadian Acquires Complete Stake in Vegenics II-48
    Takeda Acquires Millennium Pharmaceuticals II-48
    GlaxoSmithKline Forms Alliance with OncoMed for Developing
    Cancer Therapeutics II-48
    Cyclacel Signs Agreement to Acquire ALIGN Pharmaceuticals II-49
    Biogen and Genentech to Jointly Develop and Commercialize New
    Blood Cancer Drug II-49
    Aegera Therapeutics Acquires LymphoSign Inc II-49
    Velcade Gains Subsidy II-50
    Inex Pharmaceuticals Spins Off Biotechnology Business into
    Tekmira Pharmaceuticals II-50
    MilleGen Enters into Collaboration with LFB II-50
    Access Pharmaceuticals to Acquire Somanta II-50
    TopoTarget to Acquire Apoxis SA II-51
    Genentech Inks Exclusive Global Licensing Agreement with
    Seattle Genetics II-51
    Celgene Agrees to Acquisition of Pharmion II-51
    PerkinElmer Plans Acquisition of ViaCell II-51
    Favrille Announces Acquisition of Monoclonal Antibody Range
    from Diversa II-52
    Johnson & Johnson Secures Contract worth US$112 Million II-52
    Bioniche Pharma to Acquire Branded Pharmaceutical from Nabi
    Biopharmaceuticals II-52
    Takara Bio's RetroNect Used for Clinical Trials of Gene
    Therapy in Australia II-52
    Millennium Pharmaceuticals to Take Over AnorMED II-53
    MDS Pharma Services Becomes Recommended CRO for Multiple
    Myeloma Drug R&D II-53
    Celgene Certifies McKesson Specialty to Launch Revlimid II-53
    Medarex and PacMab to Co-Develop Blood Cancer Therapies II-53
    Gamida Cell and Teva to Co-Develop Therapy for Hematological
    Malignancies II-54
    GlaxoSmithKline to Take Over Praecis Pharmaceuticals II-54
    Biotest Acquires ImmunoGen Anticancer Technology Rights II-54
    Hana Signs Licensing Agreement with Inex II-54
    Cephalon Acquires Zeneus II-54

    5. Focus on Select Players II-55
    Amgen Inc (USA) II-55
    Avalon Pharmaceuticals, Inc. (USA) II-55
    Bristol-Myers Squibb Company (USA) II-55
    Kosan Biosciences, Inc. (USA) II-55
    Celgene Corporation (USA) II-56
    F. Hoffmann-La Roche Ltd (Switzerland) II-56
    Genentech, Inc. (USA) II-56
    Genta Incorporated (USA) II-56
    Millennium Pharmaceuticals (USA) II-57
    Ortho Biotech Products, LP (USA) II-57
    Seattle Genetics (USA) II-57
    Ziopharm Oncology, Inc. (USA) II-57

    6. Market Perspective II-59
    Table 11: US Recent Past, Current & Future Analysis for
    Multiple Myeloma Therapeutics by Drug - Thalomid, Revlimid,
    Velcade, and Others Independently Analyzed with Annual Sales
    Figures in US$ Million for Years 2006 through 2015 (includes
    corresponding Graph/Chart) II-59

    Table 12: US 10-Year Perspective for Multiple Myeloma
    Therapeutics by Drug - Percentage Breakdown of Dollar Sales
    for Thalomid, Revlimid, Velcade, and Others for Years 2006,
    2009 & 2015 (includes corresponding Graph/Chart) II-59

    Table 13: US Recent Past, Current & Future Analysis for
    Multiple Myeloma Therapeutics by Line of Treatment - Induction
    Therapy for SCT Candidates, Induction Therapy for Non-SCT
    Candidates, and Therapy for Relapsed or Refractory Myeloma
    Independently Analyzed with Annual Sales Figures in US$
    Million for Years 2006 through 2015 (includes corresponding
    Graph/Chart) II-60

    Table 14: US 10-Year Perspective for Multiple Myeloma
    Therapeutics by Line of Treatment - Percentage Breakdown of
    Dollar Sales for Induction Therapy for SCT Candidates,
    Induction Therapy for Non-SCT Candidates, and Therapy for
    Relapsed or Refractory Myeloma for Years 2006, 2009 & 2015
    (includes corresponding Graph/Chart) II-60

    III. COMPETITIVE LANDSCAPE

To order this report:

World Multiple Myeloma Therapeutics Market

http://www.reportlinker.com/p0119496/World-Multiple-Myeloma-Therapeutics-Market.html?utm_source=PRNWire&utm_medium=PR&utm_campaign=PRNWire

More market research reports here!


'/>"/>
SOURCE Reportlinker
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Virginia Tech Report Has National Importance
2. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
3. GAO Report Confirms: Medicare Underpays for Anesthesia Services; Nurse Anesthetists Assure Seniors Access to Safe Anesthesia Care
4. Haemacure Reports Third Quarter 2007 Results
5. Report on patients access to cancer drugs uses flawed methods to reached flawed conclusions
6. Biotech Finishes on a High in August, Burrill Report Says
7. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
8. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
9. MDS Reports Third Quarter 2007 Results
10. First New York/New Jersey Health Care Report Card Released
11. Authentidate Holding Corp. to Report Fourth Quarter and Fiscal 2007 Year End Results on Thursday, September 13, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... Encinitas, CA (PRWEB) , ... February 08, 2016 ... ... study showing greater than 50% lower incidence rate of type 2 diabetes in ... national averages. ”It is time to make a change in public health,” states ...
(Date:2/8/2016)... , ... February 08, 2016 , ... TopConsumerReviews.com recently awarded ... Mole removal products. , Moles are derived from a cluster of melanin when exposed ... the wrong places and create a lifetime of embarrassment. Historically, mole removal ...
(Date:2/8/2016)... ... February 08, 2016 , ... Guruji Mahendra Kumar Trivedi is offering ... 2016 in honor of his birthday on February 10th. During this time, people ... is known by over 250,000 people from over 40 different countries as an “ordinary ...
(Date:2/8/2016)... ... 08, 2016 , ... According to research by the National ... technicians to be certified or obtain continuing education. To increase patient awareness of ... Your Mouth?” campaign to inform dentists and patients about the possible lack of ...
(Date:2/7/2016)... (PRWEB) , ... February 07, 2016 , ... Women's Excellence ... National Wear Red Day. National Wear Red Day is the first Friday each ... Heart disease and stroke cause 1 in 3 deaths among women each year – ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... , Feb. 8, 2016   HighPoint ... November Research Group (NRG),s pharmacovigilance technology services division.  ... consulting services and an Oracle Argus Specialized partner, ... to Life Sciences companies. --> ... expands HighPoint,s life sciences capabilities and provides a ...
(Date:2/8/2016)... PALO ALTO, Calif. , Feb. 8, 2016 ... and Kodiak Sciences Inc., a biopharmaceutical company designing and ... announced today agreements for the clinical supply of Kodiak,s ... at multiple sites, including Slough (UK), Visp (CH) and ... --> Retinal diseases, such as age-related macular degeneration ...
(Date:2/8/2016)... , Feb. 8, 2016  Avista Pharma Solutions ("Avista ... Setzer as Chief Financial Officer (CFO). Mr. Setzer is ... of experience in various roles within growing technology and ... served as the Executive Director of Finance at INC ... Raleigh, NC . Previously, Mr. Setzer served ...
Breaking Medicine Technology: